Novavax Inc vs United Airlines Holdings Inc — how do they compare? Novavax Inc trades at $8.12 (market cap $1.30B), while United Airlines Holdings Inc trades at $118.05 (market cap $38.15B). The key difference: United Airlines Holdings Inc is far larger — about 29.3× Novavax Inc's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | UAL | |
|---|---|---|
Market Cap | $1.30B | $38.15B |
Sector | Health | Industrials |
52-Week High | $11.19 | $136.11 |
52-Week Low | $6.22 | $84.57 |
Enterprise Value | $800.50M | $55.18B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
United Airlines (UAL) trades at $117.68, up 1.97% on the day, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $1.99 exceeding expectations. Revenue growth is robust, reaching $59.07B in 2025, and profitability metrics like a 5.56% net income margin and 23.25% ROE reflect operational strength. Recent news highlights labor agreements and resilient travel demand despite fuel cost pressures.
The outlook for UAL is positive, driven by strong travel demand and premium revenue growth, with a consensus price target of $163.75 implying significant upside. Risks include volatile fuel prices and operational disruptions, but the company's guidance for 2026 EPS of $9–$11 and improving cash flow trends support a favorable investment case for growth-oriented investors.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →